^
Association details:
| Biomarker: | ERCC1 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer
Excerpt:
We tested the effect of BMN 673 in our ERCC1-isogenic system and found that ERCC1-deficient clones were significantly more sensitive to BMN 673 than their ERCC1-proficient counterparts (Figure 2f; Supplementary Table S1). Consistent with the enhanced potency of this compound, the ERCC1-selective effect of BMN 673 was achieved at considerably lower concentrations of PARP1/2 inhibitor than for the other clinical inhibitors...
